Reduced moxifloxacin exposure in patients with tuberculosis and diabetes
| Autor: | Lies ter Beek, Jan-Willem C. Alffenaar, Mathieu S. Bolhuis, Tjip S. van der Werf, Bart G. J. Dekkers, Onno W. Akkerman, Wiel C M de Lange |
|---|---|
| Přispěvatelé: | Prevention and Public Health, Microbes in Health and Disease (MHD) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Pulmonary and Respiratory Medicine
Drug Adult Male medicine.medical_specialty Tuberculosis media_common.quotation_subject Moxifloxacin Antitubercular Agents MEDLINE Comorbidity Dose-Response Relationship 03 medical and health sciences 0302 clinical medicine Internal medicine Diabetes mellitus medicine Diabetes Mellitus Humans In patient 030212 general & internal medicine Moxifloxacin/administration & dosage media_common Tuberculosis/drug therapy Dose-Response Relationship Drug business.industry Antitubercular Agents/administration & dosage Middle Aged bacterial infections and mycoses medicine.disease Dose–response relationship 030228 respiratory system Female business medicine.drug |
| Zdroj: | European Respiratory Journal, 54(3):A15. European Respiratory Society European Respiratory Journal, 54(3):1900373. EUROPEAN RESPIRATORY SOC JOURNALS LTD Dekkers, B G J, Bolhuis, M S, Ter Beek, L, de Lange, W C M, van der Werf, T S, Alffenaar, J-W C & Akkerman, O W 2019, ' Reduced moxifloxacin exposure in patients with tuberculosis and diabetes ', European Respiratory Journal, vol. 54, no. 3, A15 . https://doi.org/10.1183/13993003.00373-2019 |
| ISSN: | 1399-3003 0903-1936 |
| DOI: | 10.1183/13993003.00373-2019 |
| Popis: | Exposure to moxifloxacin is low in patients with tuberculosis and diabetes comorbidity due to increased clearance of the drug. As low exposure may result in poor treatment outcomes, higher moxifloxacin doses may be required for treatment success.http://bit.ly/2Ynxdf7 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|